East Hanover Archives - 2021 CMSC Annual Meeting

October 25, 2021

COVID-19 Impact on Loneliness and Rates of Depression and Anxiety in Individuals with MS

Background: The COVID-19 pandemic has resulted in a decline in mental health, due to the stress imposed by direct effects (e.g., loss of...

October 25, 2021

Evaluation of Apathy in Multiple Sclerosis

Background: Features of apathy include lack of initiation, lack of interest, reduced spontaneity, indifference, and reduced self-awareness....

October 25, 2021

Passive Monitoring of Cognition Using a Smartphone Application in MS

Background: Cognitive impairment is one of the most common and debilitating symptoms of multiple sclerosis (MS). Traditional...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Efficacy of Ofatumumab on Microglial Activity in Patients with Relapsing Forms of Multiple Sclerosis: Interim Analysis

INTRODUCTION Ofatumumab, a fully-human anti-CD20 monoclonal antibody, is indicated for the treatment of relapsing forms of multiple...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Agnos Study Design: A Phase 4 Study Assessing Ofatumumab in Treatment-Naïve Young Adults with Early Relapsing Remitting MS Benchmarked Against Healthy Controls

Background: Early intervention with high efficacy therapies has been shown to reduce long-term disability accrual in patients with multiple...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Long-Term Effect of Siponimod on MRI Outcomes in Secondary Progressive Multiple Sclerosis: Analyses from the Expand Study up to 5 Years

Background: In the Phase 3 EXPAND core study, siponimod compared with placebo significantly reduced disability progression, cognitive...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Safety and Efficacy of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis Identifying As Hispanic from the Expand Study

Background: In the Phase 3 EXPAND trial siponimod, a selective S1P receptor modulator, significantly reduced risk of 3-month and 6-month...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Multiple Sclerosis Patients Initiating Ofatumumab in the Real-World: Early 3 Months Data

Background: The efficacy and safety of ofatumumab were demonstrated in Phase III ASCLEPIOS trials. This analysis provides the first account...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Evaluating Perceptions of Ofatumumab in Multiple Sclerosis Via Social Media Listening Early 3 Months Post Approval Data

Background: Superior efficacy and safety of ofatumumab were demonstrated in Phase III ASCLEPIOS trials. Objectives: The social media...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Analyses of the Effect of Baseline Age on the Efficacy and Safety of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis from the Expand Study

Background: Siponimod is a selective S1P receptor (S1P1 and S1P5) modulator, approved in the USA for treatment of relapsing forms of MS,...

Read More →

2021 CMSC Annual Meeting

Tag: East Hanover

COVID-19 Impact on Loneliness and Rates of Depression and Anxiety in Individuals with MS

Evaluation of Apathy in Multiple Sclerosis

Passive Monitoring of Cognition Using a Smartphone Application in MS

Efficacy of Ofatumumab on Microglial Activity in Patients with Relapsing Forms of Multiple Sclerosis: Interim Analysis

Agnos Study Design: A Phase 4 Study Assessing Ofatumumab in Treatment-Naïve Young Adults with Early Relapsing Remitting MS Benchmarked Against Healthy Controls

Long-Term Effect of Siponimod on MRI Outcomes in Secondary Progressive Multiple Sclerosis: Analyses from the Expand Study up to 5 Years

Safety and Efficacy of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis Identifying As Hispanic from the Expand Study

Multiple Sclerosis Patients Initiating Ofatumumab in the Real-World: Early 3 Months Data

Evaluating Perceptions of Ofatumumab in Multiple Sclerosis Via Social Media Listening Early 3 Months Post Approval Data

Analyses of the Effect of Baseline Age on the Efficacy and Safety of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis from the Expand Study

MAILING ADDRESS

CONTACT US

FOLLOW US